Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular and Thrombotic Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GP6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GP6 ECD-Fc Fusion Protein / Monomeric His-tag Protein HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled, Sequence Verified. Designed for dimeric conformation mimicking and collagen-binding competition assays. |
View GP6 Products |
| Gene Delivery | GP6 Promise-ORF / Lentivirus Full-length human GP6 ORF for stable cell line generation. Ideal for cell-based flow cytometry and signaling validation. |
View GP6 Products |
| Benchmark Ab | Anti-GP6 Recombinant Antibody (Glenzocimab Biosimilar) Recombinant humanized Fab fragment positive control for functional blocking and affinity comparison. |
View GP6 Products |
| Validator | GP6 siRNA Set Target-specific siRNA pools for gene knockdown verification in megakaryocytic cell lines. |
View GP6 Products |
| Related Target A | COL1A1 (Collagen Type I Alpha 1) Primary physiological ligand of GP6. Essential for establishing GP6-collagen binding inhibition assays. |
View COL1A1 Products |
| Related Target B | CLEC2 (CLEC1B) Platelet activation receptor operating in parallel pathways. Crucial for off-target selectivity screening in anti-thrombotic drug discovery. |
View CLEC2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dimeric Conformation Mimicry | GP6 ECD-Fc fusion proteins designed to form natural homodimers, providing high-affinity collagen binding kinetics mimicking native platelets. |
| Cross-Species Cross-Reactivity Testing | Human, Cynomolgus, and Mouse GP6 recombinant proteins available with strict mass spectrometry sequence verification. |
| Lack of Validated Positive Controls | Inclusion of sequence-verified Glenzocimab (anti-GP6 Fab) biosimilar as a benchmark control. |
| Target Specificity Verification | Sequence-verified siRNA sets and parallel screening antigens (CLEC2) to eliminate false positives. |
Live GP6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GP6 therapeutics is intensifying, with major players shifting focus from traditional systemic anticoagulants to targeted antiplatelet agents that do not prolong bleeding time. As first-generation GP6 inhibitors reach advanced clinical phases, the next wave of R&D is targeting acute ischemic stroke, myocardial infarction, and arterial thrombosis without the associated bleeding risks of standard-of-care therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fab Fragment | Acticor Biotech (Glenzocimab) | Acute Ischemic Stroke, STEMI | Affinity and blocking assays requiring sequence-verified GP6 ECD-Fc and benchmark antibodies. |
| Fc-Fusion Protein | advanceCOR (Revacept) | Stroke, CAD, Atherosclerosis | Competitive collagen-binding assays requiring high-purity COL1A1 and active GP6 dimers. |
| Small Molecule | Academic/Biotech Consortia | Thrombosis Prevention | High-throughput screening assays utilizing Lentivirus-driven stable GP6-expressing cell lines. |